Adjuvant Ovarian Suppression in Premenopausal Breast Cancer.

Authors :: Francis, Prudence A.
Regan, Meredith M.
Fleming, Gini F.
Láng, István
Ciruelos, Eva
Bellet, Meritxell
Bonnefoi, Herve R.
Climent, Miguel A.
Da Prada, Gian Antonio
Burstein, Harold J.
Martino, Silvana
Davidson, Nancy E.
Geyer Jr., Charles E.
Walley, Barbara A.
Coleman, Robert
Kerbrat, Pierre
Buchholz, Stefan
Ingle, James N.
Winer, Eric P.
Rabaglio-Poretti, Manuela
Source :: New England Journal of Medicine. 1/29/2015, Vol. 372 Issue 5, p436-446. 11p. 1 Diagram, 2 Charts, 2 Graphs.
Publication Year :: 2015
Abstract: The article focuses on suppression of ovarian estrogen to reduce recurrence of hormone-receptor-positive early breast cancer in premenopausal women. Topics discussed include a comparison of adjuvant tamoxifen plus ovarian suppression and tamoxifen only on preventing premenopausal breast cancer, the effectiveness of combined tamoxifen and ovarian suppression and reduction of breast cancer risk seen after combined tamoxifen and ovarian suppression.